日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.

亲和力通过靶向介导的药物处置影响抗GD2抗体的功能效力

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17152510
Troschke-Meurer Sascha, Zumpe Maxi, Ahrenberg Peter Moritz, Ebeling Torsten, Siebert Nikolai, Grabarczyk Piotr, Lode Holger N
免疫/内分泌
发表日期：2025
文献求助 收藏

A 3D Model of Human Buccal Mucosa for Compatibility Testing of Mouth Rinsing Solutions

用于漱口水相容性测试的人体颊黏膜三维模型

期刊:Pharmaceutics
影响因子:5.5
doi:10.3390/pharmaceutics15030721
Zwicker, Paula; Zumpe, Maxi; Kramer, Axel; Müller, Gerald
Human
发表日期：2023
文献求助 收藏

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy

N5和N6化疗周期联合Dinutuximab Beta治疗复发性高危神经母细胞瘤患者（至少接受过一种二线治疗）的疗效和耐受性

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers15133364
Lode, Holger N; Ladenstein, Ruth; Troschke-Meurer, Sascha; Struppe, Linda; Siebert, Nikolai; Zumpe, Maxi; Ehlert, Karoline; Huber, Stefanie; Glogova, Evgenia; Hundsdoerfer, Patrick; Eggert, Angelika; Zaniewska-Tekieli, Anna; Balwierz, Walentyna; Wieczorek, Aleksandra
细胞生物学
发表日期：2023
文献求助 收藏

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta.

免疫细胞因子 FAP-IL-2v 增强抗 GD(2) 抗体 Dinutuximab Beta 的抗神经母细胞瘤疗效

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers14194842
Siebert Nikolai, Leopold Justus, Zumpe Maxi, Troschke-Meurer Sascha, Biskupski Simon, Zikoridse Alexander, Lode Holger N
神经科学
细胞生物学
发表日期：2022
文献求助 收藏

Reduction of CD11b(+) myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD(2) antibody ch14.18/CHO.

CD11b(+)髓系抑制细胞的减少增强了抗GD(2)抗体ch14.18/CHO诱导的抗神经母细胞瘤免疫反应

期刊:Oncoimmunology
影响因子:6.3
doi:10.1080/2162402X.2020.1836768
Siebert Nikolai, Zumpe Maxi, von Lojewski Leon, Troschke-Meurer Sascha, Marx Madlen, Lode Holger N
神经科学
CD11B
发表日期：2020
文献求助 收藏

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial

HACA对ch14.18/CHO长期输注白细胞介素-2后免疫调节和治疗毒性的影响：SIOPEN II期试验结果

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers10100387
Siebert, Nikolai; Troschke-Meurer, Sascha; Marx, Madlen; Zumpe, Maxi; Ehlert, Karoline; Gray, Juliet; Garaventa, Alberto; Manzitti, Carla; Ash, Shifra; Klingebiel, Thomas; Beck, James; Castel, Victoria; Valteau-Couanet, Dominique; Loibner, Hans; Ladenstein, Ruth; Lode, Holger N
细胞生物学
毒理研究
免疫/内分泌
发表日期：2018
文献求助 收藏